📊 BOLD Key Takeaways
Investment Thesis
Boundless Bio is a pre-revenue pharmaceutical company with severe operational losses (-$63.6M operating income) and negative free cash flow (-$47.2M), indicating the company is consuming cash at an unsustainable rate. With only $17.9M in cash against $46.7M annual operating burn, the company faces a critical liquidity crisis within months without additional financing. The company shows no clear path to profitability or revenue generation based on available financial data.
BOLD Strengths
- Strong balance sheet structure with minimal debt (0.00x debt/to-equity)
- Excellent short-term liquidity with 8.74x current ratio despite operational losses
- Biotech sector allows for transformative potential if pipeline succeeds
BOLD Risks
- Severe cash burn rate ($46.7M annual operating outflow) with only $17.9M cash runway (~4.6 months)
- No revenue generation with $63.6M operating losses in pharmaceutical development stage
- Negative ROE (-59.0%) and ROA (-37.1%) demonstrate value destruction and poor asset utilization
- Pre-clinical/early-stage biotech company faces high clinical development risk and regulatory uncertainty
- Likely requires immediate equity dilution or debt financing to avoid insolvency
Key Metrics to Watch
- Cash runway and quarterly burn rate to assess survival timeline
- Clinical trial progress and pipeline advancement announcements
- Future financing activities and dilution impact on shareholder value
BOLD Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.74x current ratio provides a solid financial cushion.
BOLD Profitability Ratios
BOLD vs Healthcare Sector
How Boundless Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BOLD Balance Sheet & Liquidity
BOLD 5-Year Financial Trend
5-Year Trend Summary: Boundless Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.85 indicates the company is currently unprofitable.
BOLD Growth Metrics (YoY)
BOLD Capital Allocation
BOLD SEC Filings
Access official SEC EDGAR filings for Boundless Bio, Inc. (CIK: 0001782303)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BOLD
What is the AI rating for BOLD?
Boundless Bio, Inc. (BOLD) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BOLD's key strengths?
Strong balance sheet structure with minimal debt (0.00x debt/to-equity). Excellent short-term liquidity with 8.74x current ratio despite operational losses.
What are the risks of investing in BOLD?
Severe cash burn rate ($46.7M annual operating outflow) with only $17.9M cash runway (~4.6 months). No revenue generation with $63.6M operating losses in pharmaceutical development stage.
What is BOLD's revenue and growth?
Boundless Bio, Inc. reported revenue of N/A.
Does BOLD pay dividends?
Boundless Bio, Inc. does not currently pay dividends.
Where can I find BOLD SEC filings?
Official SEC filings for Boundless Bio, Inc. (CIK: 0001782303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BOLD's EPS?
Boundless Bio, Inc. has a diluted EPS of $-2.60.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.